NCT01068951

Treatment of Patients With Newly Onset of Type 1 Diabetes With Mesenchymal Stem Cells

Open Study to Evaluate the Safety and Efficacy of Autologous Mesenchymal Stem Cells in Treatment of Recently Diagnosed Patients With Type 1 Diabetes Mellitus

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Uppsala University Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

The main hypothesis of the investigators study is that the development of autoimmune diabetes may be halted att diagnosis by the immune modulatory properties of mesenchymal stem cells.

Conditions

• Type 1 Diabetes

Interventions

Type	Name	Description
BIOLOGICAL	Mesenchymal stem cells	Autologous transplantation of the patients own mesenchymal stem cells (approximately 2 x 106 cells/kg body weight) intravenously.

Timeline

• Start date: 2010-06-01
• Primary completion: 2013-09-01
• Completion: 2013-09-01
• First posted: 2010-02-17
• Last updated: 2014-02-05

Locations

1 site across 1 country: Sweden